- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04514471
Mulighetsstudie - Filterventilasjon
Mulighet for å gjennomføre en telehelsestudie som vurderer fjerning av filterventilasjon på røykeatferd og biomarkører
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55405
- University of Minnesota
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Beskrivelse
Inklusjonskriterier:
- 21 år eller eldre
- Vanlig sigarettrøyker
- Røyker for tiden et kvalifisert merke
- Generelt god helse
- Tilgang til smarttelefon eller nettbrett og en enhet med fungerende kamera for telehelsebesøk. Må også ha internettilgang.
Ekskluderingskriterier:
- Ustabil helse
- Ukontrollert høyt blodtrykk
- Gravid eller ammende
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Menthol Cigarette Smokers Group 1
Smokers regularly using menthol cigarettes (at least 80% of the time ) who meet eligibility criteria will enter 2 weeks of monitoring of usual brand smoking.
Randomized to ventilated non-menthol cigarettes.
|
4 week intervention where participants will be using ventilated non-menthol cigarettes. Weekly telehealth visits will be conducted during baseline and the 4 weeks on study cigarettes to collect study measures followed by a follow-up one month after end of intervention. |
|
Aktiv komparator: Menthol Cigarettes Smokers Group 2
Smokers regularly using menthol cigarettes (at least 80% of the time ) who meet eligibility criteria will enter 2 weeks of monitoring of usual brand smoking.
Randomized to minimally ventilated non-menthol cigarettes.
|
4 week intervention where participants will be using minimally ventilated non-menthol cigarettes. Weekly telehealth visits will be conducted during baseline and the 4 weeks on study cigarettes to collect study measures followed by a follow-up one month after end of intervention. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants That Dropped Out
Tidsramme: Baseline through Week 4
|
Percentage of Participants that dropped out by week 4.
|
Baseline through Week 4
|
|
Feasibility of Approach - Data Collection
Tidsramme: Baseline through Week 4
|
Percent reporting difficulty collecting data in the Study Feasibility Questionnaire and interview
|
Baseline through Week 4
|
|
Cigarettes Smoked Per Day
Tidsramme: Baseline through Week 4
|
Change in mean Cigarettes Per Day (CPD) based on 7 day ITR data before visit.
Randomized participants (low vs moderate FV), between-group difference in change in cigarettes per day from baseline to Week 4, comparing low-ventilated versus moderate-ventilated non-menthol cigarette groups.
Cigarettes per day (CPD) was calculated as the mean number of cigarettes smoked per day based on daily self-reported cigarette use collected via interactive text response (ITR) surveys.
Change scores were computed as the difference between the mean CPD at Week 4 and the mean CPD at baseline for each participant, and group differences reflect the between-arm difference in these change scores.
|
Baseline through Week 4
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cotinine Change
Tidsramme: Baseline through week 4
|
Change in cotinine from baseline to the week 4 visit.
Randomized participants (low vs moderate FV), between-group difference in cotinine from baseline to Week 4, comparing low-ventilated versus moderate-ventilated non-menthol cigarette groups.
Cotinine was measured from blood samples collected using volumetric absorptive micro sampling (VAMS) and analyzed using liquid chromatography-mass spectrometry.
Due to skewness, cotinine values were log-transformed, and change was calculated as the log ratio of Week 4 to baseline levels.
Group differences represent the between-arm difference in these log-transformed changes.
|
Baseline through week 4
|
|
Carbon Monoxide Changes
Tidsramme: Baseline through Week 4
|
Change in Carbon Monoxide from baseline to the week 4 visit.
Randomized participants (low vs moderate FV), between-group difference in carbon monoxide from baseline to Week 4, comparing low-ventilated versus moderate-ventilated non-menthol cigarette groups.
Exhaled carbon monoxide (ppm) was measured remotely using a portable CO monitor during scheduled study visits.
Change scores were calculated as Week 4 minus baseline CO levels for each participant, and group differences represent the between-arm difference in these change scores.
|
Baseline through Week 4
|
|
Quit Attempts
Tidsramme: Baseline through Week 4
|
Number of 24 hour quit attempts analyzed using regression estimate.
Randomized participants (low vs moderate FV), between-group difference in quit attempt from baseline to Week 4, comparing low-ventilated versus moderate-ventilated non-menthol cigarette groups.
|
Baseline through Week 4
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Dorothy Hatsukami, PH.D, Masonic Cancer Center, University of Minnesota
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 2020LS110
- 5P01CA217806 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .